A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
Infantile-onset Pompe disease is a rare condition that causes muscle weakness, breathing difficulties, and heart problems due to a missing enzyme. Children are usually treated with regular enzyme replacement therapy called alglucosidase alfa. However, for some children, this treatment stops working as well over time, or their symptoms begin to worsen. This clinical trial is testing a newer version of the enzyme medicine, called avalglucosidase alfa, in children aged 6 months to 17 years. The study aims to see if this medicine is safe and better at reaching the muscles that need it. Participants receive the medicine through a drip into a vein every two weeks. Because Pompe disease requires ongoing care, researchers will monitor the children's heart, lungs, and muscle strength over several years to understand the long-term benefits and safety.
Em resumo
Resultados
Resultados deste estudo
Publicado November 2021Os resultados foram publicados para este estudo.
Sobre o que é este estudo?
Pompe disease is a rare, inherited condition where the body cannot make enough of an enzyme called acid alpha-glucosidase. Without this enzyme, a type of sugar called glycogen builds up inside the body's cells. Over time, this buildup damages muscles, particularly the heart and the muscles used for moving and breathing.
The standard treatment is enzyme replacement therapy using a medicine called alglucosidase alfa, given through a drip. While this treatment has saved many lives, some children find that their symptoms stop improving or begin to decline after a period of time. They may develop weaker muscles, extra breathing difficulties, or droopy eyelids.
This clinical study focuses on a modified treatment called avalglucosidase alfa. Scientists designed this newer medicine to be absorbed more easily by muscle cells, hoping it will clear glycogen more effectively. The study is investigating whether switching to this medicine can help stabilise or improve health in children whose current treatment is not giving the best results.
By following participants over several years, doctors hope to learn whether this treatment is safe for long-term use in children and how well it supports their day-to-day movement, breathing, and heart function.
Pontos principais
- Tests a newer enzyme treatment for children with infantile-onset Pompe disease.
- Aimed at young people whose current treatment is no longer working well enough.
- Medicine is given through a drip once every two weeks.
- Monitors heart, lung, and muscle health over several years.
- Participation is completely voluntary and you can withdraw at any time.
Quem pode ser elegível?
This trial is for babies, children, and teenagers aged between 6 months and 17 years who have a confirmed diagnosis of infantile-onset Pompe disease. Participants must have had an enlarged heart (cardiomyopathy) when they were first diagnosed.
To take part, children must have already been receiving regular doses of the standard enzyme medicine (alglucosidase alfa) for at least six months. In addition, their doctor must have noticed that their condition is either declining or not improving as well as hoped in areas such as movement, breathing, heart function, or eyelid control.
Children cannot join the study if they have very high levels of antibodies against the enzyme therapy, or if they have a known high risk of severe allergic reactions to these types of treatments.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Child is aged between 6 months and 17 years old.
- Has a confirmed diagnosis of infantile-onset Pompe disease.
- Had heart enlargement (cardiomyopathy) when first diagnosed.
- Has been on stable alglucosidase alfa treatment for at least six months.
- Shows signs of worsening symptoms or limited progress with current therapy.
O que envolve a participação?
Taking part in this study involves receiving the study medicine through an intravenous (IV) drip into a vein once every two weeks. Before treatment begins, your child will have a screening period lasting between two and four weeks to confirm that the study is safe and suitable for them.
The initial treatment period lasts 25 weeks, followed by a long-term extension period that can continue for several years. During clinic visits, the medical team will carry out regular health checks. These include blood tests, heart scans (such as echocardiograms), physical movement assessments, and breathing tests. After the treatment period ends, there is a four-week follow-up period to check on your child's wellbeing.
Riscos e benefícios potenciais
Locations (12)
- Regional Medical Genetics Center of New York Site Number : 8400002Código postal verificadoValhalla, United States
- Duke University Medical Center Site Number : 8400001Código postal verificadoDurham, Estados Unidos
- Seattle Childrens Hospital and Regional Medical Center- Site Number : 8400005Código postal verificadoSeattle, Estados Unidos
- Investigational Site Number : 2500004Código postal verificadoNantes, França
- Investigational Site Number : 2500003Código postal verificadoParis, França
- Investigational Site Number : 2500002Código postal verificadoParis, França
- Investigational Site Number : 2500001Código postal verificadoTours, France
- Investigational Site Number : 3920001Apenas cidadeFuchu-shi, Japan
- Investigational Site Number : 3920002Apenas cidadeFuchu-shi, Japan
- Investigational Site Number : 1580001Código postal verificadoHsinchu, Taiwan
- Investigational Site Number : 8260001Código postal verificadoLondres, Reino Unido
- Investigational Site Number : 8260002Código postal verificadoManchester, Reino Unido
Perguntas frequentes
How is the study medicine given?
It is given as an infusion through a drip into a vein once every two weeks at the study clinic.
Does my child have to stop their current treatment?
Children in this study will either switch to the new study medicine or be compared against standard treatment, depending on which group they enter. The study team will guide you through this process.
How long will my child be in the study?
Because Pompe disease requires lifelong management, this study includes a long-term follow-up that can last up to nine years, ensuring children receive continuous monitoring.
Will taking part cost us anything?
No, the study medicine and all trial-related tests are provided free of charge. Travel costs and related expenses are often covered by the study sponsor.
Can we leave the trial if we change our minds?
Yes, you can leave the study at any point. Deciding to withdraw will not affect your child's relationship with their doctors or their ongoing medical care.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.